David L DeRemer
Overview
Explore the profile of David L DeRemer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
George T, Lee J, DeRemer D, Hosein P, Staal S, Markham M, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400406.
PMID: 39626160
Purpose: BRCA1-associated protein 1 (BAP1) is a critical cell cycle and DNA damage response (DDR) regulator with mutations (mBAP1) causing a functional protein loss. PARP inhibitors (PARPis) demonstrate synthetic lethality...
2.
Cicali E, Eddy E, Gong Y, Elchynski A, Pena Del Aguila K, Basha T, et al.
Clin Transl Sci
. 2024 Jul;
17(7):e13890.
PMID: 39046302
The University of Florida Health conducted a pragmatic implementation of a pharmacogenetics (PGx) panel-based test to guide medications used for supportive care prescribed to patients undergoing chemotherapy. The implementation was...
3.
Luboff A, DeRemer D
Ann Pharmacother
. 2024 Apr;
58(12):1229-1237.
PMID: 38566315
Objective: To review the pharmacology, efficacy, and safety of capivasertib for the treatment of adults with hormone receptor-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer with 1 or more...
4.
Bruno K, ODell W, Tantawy M, Casson C, Ferrall-Fairbanks M, DeRemer D, et al.
Am Heart J Plus
. 2024 Mar;
37:100348.
PMID: 38510509
No abstract available.
5.
Allen J, Awunti M, Guo Y, Bian J, Rogers S, Scarton L, et al.
Cancer Epidemiol Biomarkers Prev
. 2023 Oct;
32(12):1675-1682.
PMID: 37788369
Background: Supportive care medication use differences may contribute to racial disparities observed in health-related quality of life in patients with pancreatic cancer. Methods: In this observation study using the Surveillance,...
6.
Singhal R, Rogers S, Lee J, Ramnaraign B, Sahin I, Fabregas J, et al.
Future Oncol
. 2023 Sep;
19(27):1841-1851.
PMID: 37753702
For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy. FOLFIRINOX is a combination chemotherapy regimen that offers...
7.
DeRemer D, Nguyen N, Guha A, Ahmad F, Cooper-DeHoff R, Pepine C, et al.
J Am Heart Assoc
. 2023 May;
12(10):e027981.
PMID: 37158063
Background Anthracyclines remain a key treatment for many malignancies but can increase the risk of heart failure or cardiomyopathy. Specific guidelines recommend echocardiography and serum cardiac biomarkers such as BNP...
8.
DeRemer D, Doonan B
Oncology (Williston Park)
. 2023 Apr;
37(3):138-139.
PMID: 37094287
No abstract available.
9.
Awunti M, DeRemer D, Rogers S, Scarton L, Adkins L, Wilkie D, et al.
J Am Coll Clin Pharm
. 2023 Feb;
5(12):1284-1296.
PMID: 36844700
There is surmounting levels of evidence on the health disparities within cancer treatment in the United States (US). Most of the research focused on cancer specific factors including anticancer incidence,...
10.
Telisnor G, DeRemer D, Frimpong E, Agyare E, Allen J, Ricks-Santi L, et al.
J Natl Med Assoc
. 2023 Feb;
115(2):164-174.
PMID: 36801148
Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer mortality and the incidence is projected to increase by 2030. Despite recent advances in its treatment, African Americans...